Growth Metrics

Amphastar Pharmaceuticals (AMPH) Income from Continuing Operations: 2012-2024

Historic Income from Continuing Operations for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $148.4 million.

  • Amphastar Pharmaceuticals' Income from Continuing Operations fell 57.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year decrease of 35.76%. This contributed to the annual value of $148.4 million for FY2024, which is 8.91% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Income from Continuing Operations of $148.4 million as of FY2024, which was up 8.91% from $136.2 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Income from Continuing Operations peaked at $148.4 million during FY2024, and registered a low of $1.1 million during FY2020.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Income from Continuing Operations value was $136.2 million (recorded in 2023), while the average stood at $124.1 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Income from Continuing Operations plummeted by 98.27% in 2020 and then skyrocketed by 5,689.33% in 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' Income from Continuing Operations (MRY) stood at $1.1 million in 2020, then skyrocketed by 5,689.33% to $63.5 million in 2021, then surged by 38.32% to $87.8 million in 2022, then soared by 55.08% to $136.2 million in 2023, then rose by 8.91% to $148.4 million in 2024.
  • Its Income from Continuing Operations was $148.4 million in FY2024, compared to $136.2 million in FY2023 and $87.8 million in FY2022.